Regenerx Biopharmaceuticals Inc (RGN) financial statements (2020 and earlier)

Company profile

Business Address 15245 SHADY GROVE ROAD
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1001010
Cash and cash equivalents1001010
Prepaid expense0000000
Total current assets:1001010
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment(0)000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets0      
Total noncurrent assets:0000000
TOTAL ASSETS:1001010
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0000001
Accounts payable0000001
Accrued liabilities0000000
Deferred revenue0
Debt0010  0
Derivative instruments and hedges, liabilities  1    
Deferred revenue and credits00   
Other undisclosed current liabilities 0    (0)
Total current liabilities:0021001
Noncurrent Liabilities
Long-term debt and lease obligation1 01110
Long-term debt, excluding current maturities1 01110
Liabilities, other than long-term debt2 26621
Deferred revenue and credits22100
Deferred revenue2
Derivative instruments and hedges, liabilities  04510
Other undisclosed noncurrent liabilities 2     
Total noncurrent liabilities:3226721
Total liabilities:3247732
Stockholders' equity
Stockholders' equity attributable to parent(2)(2)(4)(6)(7)(2)(2)
Common stock0000000
Additional paid in capital10510410099989895
Accumulated deficit(107)(106)(105)(105)(105)(100)(97)
Total stockholders' equity:(2)(2)(4)(6)(7)(2)(2)
TOTAL LIABILITIES AND EQUITY:1001010

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:00000  
Operating expenses(1)(1)(2)(2)(2)(2)(1)
Other undisclosed operating income      0
Operating loss:(1)(1)(1)(2)(2)(2)(1)
Nonoperating income (expense)(0)(1)2 000
Investment income, nonoperating0   000
Other nonoperating expense (1)     
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before equity method investments, income taxes:(2)(2)0(2)(2)(2)(1)
Other undisclosed income from continuing operations before income taxes000    
Income (loss) from continuing operations before income taxes:(1)(2)0(2)(2)(2)(1)
Income tax expense (benefit)00(0)    
Net income (loss):(1)(2)0(2)(2)(2)(1)
Other undisclosed net income (loss) attributable to parent(0)(0) 2(3)(1)0
Net income (loss) attributable to parent:(1)(2)00(5)(3)(1)
Other undisclosed net loss available to common stockholders, basic(0)      
Net income (loss) available to common stockholders, diluted:(1)(2)00(5)(3)(1)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(1)(2)0(2)(2)(2)(1)
Comprehensive income (loss), net of tax, attributable to parent:(1)(2)0(2)(2)(2)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: